Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone Oncology"
DOI: 10.1016/j.jbo.2022.100416
Abstract: Highlights • Skeletal-related events (SRE) with tumors have significant patient/economic burden.• Denosumab (RANKL inhibitor) is approved for SRE prevention in MM and solid tumor BM.• Denosumab reduced risk of first/subsequent SREs versus zoledronate in solid… read more here.
Keywords: skeletal related; experience denosumab; related events; prevention ... See more keywords